References
1. Dan GA, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic
drugs-clinical use and clinical decision making: a consensus document
from the European Heart Rhythm Association (EHRA) and European Society
of Cardiology (ESC) Working Group on Cardiovascular Pharmacology,
endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm
Society (APHRS) and International Society of Cardiovascular
Pharmacotherapy (ISCP). Europace. 2018;20(5):731-732an.
2. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS
Guideline for Management of Patients With Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death: A Report of the American College
of Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Heart Rhythm Society. Circulation.
2018;138(13):e272-e391.
Figure 1A. Electrocardiogram performed between episodes of
non-sustained polymorphic ventricular tachycardia: atrial fibrillation
with controlled ventricular rate, flattened T waves and slightly
prolonged corrected QT interval.
Figure 1B. Electrocardiogram performed between episodes of
sustained polymorphic ventricular tachycardia: sinus rhythm, note the
extreme corrected QT interval prolongation (more than 700 milliseconds)
and the presence of T-wave alternans (white stars).
Figure 1C. Electrocardiogram performed during drugs’ washout;
note the shorter QT interval.